The Liver Meeting (AASLD) 2026: key results and trends

Adverse events (OsrHSA, 87.8%; pHSA, 86.4%) or serious adverse events (OsrHSA, 12.2%; pHSA, 10.5%) were comparable.

The composite response rate improved up to 40% after 24 weeks off treatment in both the LNF/RTV treatment arm (EOS composite response rate of 14.2% compared to 10.1% at EOT) and in the LNF/RTV + PEG treatment arm (EOS composite response rate of 26.4% compared to 19.2% at EOT).

AEs of FSV decrease/deficiency were experienced in 4 (3%) pts receiving linerixibat and 2 (2%) pts receiving placebo, with no meaningful difference in incidence between groups.

At W48, 59.1% (13/22) of BLV pts with Baveno-VII rule-in criteria improved to GZ or ruleout vs 25.0% (1/4) of control pts.

The proportion of subjects with Cholangitis-free transplant-free survival at 12 months was 35% in the KG group and 10% in the KSt group (10%), with log-rank p = 0.0002 and Cox HR 0.36 (95% CI 0.20–0.64); composite events occurred in 18/34 KG vs 39/46 KSt.

ZSP1601 reduced liver fat content, with mean percent changes from baseline of -30% (100 mg) and -5% (50 mg) vs. +7% (placebo).

At week 12, J2H-1702, especially 200 mg, produced a significant reduction in hepatic fat by MRI-PDFF (−18.7% vs. +3.1%; LS mean difference, −22.3%; p=0.011), alongside improvements in liver enzymes, body weight, and lowdensity lipoprotein cholesterol.

Notably, at w96, advanced (complete septal and nodular) fibrosis decreased from baseline by 42% in EFX28 and 48% in EFX50, compared to -16% in Pbo (p = 0.02 and p = 0.003, respectively).

Treatment discontinuations due to AEs were rare, occurring in 0.0% and 1.2%, in the 1.2 mg and 1.8 mg groups, compared to 3.5% in the placebo group.

At week 96, 88% (28/32) of participants receiving elebsiran+tobevibart Q4W achieved undetectable HDV RNA (target not detected [TND], no amplification by PCR) and 53% (17/32) achieved ALT normalization (missing equals failure analysis).